Navigation Links
New: Longevinex(R) First to Introduce Micronized Resveratrol Matrix - Now Stabilized by Microencapsulation
Date:4/22/2008

SAN DIMAS, Calif., April 22 /PRNewswire/ -- To enhance absorption, the Longevinex(R) matrix of nutraceuticals now features micron-sized trans-resveratrol, microencapsulated in an envelope of all natural plant dextrins and starches to preserve resveratrol in its trans-resveratrol form from degradation by light, heat and oxygen. (Refs 1, 2)

(Photo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU004 )

The newly formulated Longevinex resveratrol matrix withstands direct exposure to solar ultraviolet radiation and heat in independent laboratory tests, says Bill Sardi, spokesperson for Longevinex. (To learn more about microencapsulation online, visit: http://en.wikipedia.org/wiki/Micro-encapsulation )

Microencapsulation protects resveratrol from environmental factors before it is encapsulated into a larger oral capsule. Microencapsulation also facilitates slow release and better absorption.

The ingredients in Longevinex(R) capsules are newly formulated to provide rice bran ferulate, and natural vitamin D3.

The ingredients in Longevinex(R) work additively and synergistically, says Sardi. Vitamin D3 works to breakdown rice bran IP6, a whole-grain factor also provided in Longevinex, into IP3, which is its primary active form. Quercetin allows more resveratrol to pass through the liver before it is metabolized, improving immediate bioavailability of resveratrol.

A drawback of most resveratrol supplements is their emodin content. Small amounts of emodin can induce loose stool in sensitive individuals. Resveratrol in Longevinex(R) is a purified form that is virtually emodin-free.

The newly formulated Longevinex(R) matrix is produced in a vege-capsule, to meet requirements of vegetarians.

Longevinex(R) provides a unique array of mineral chelators (patent applied for) based around an over-mineralization theory of aging, explained at its website.

Longevinex(R) is the first and only resveratrol-based dietary supplement to be shown to be efficacious in a human study (reduced markers of oxidation and inflammation among endurance athletes in independent study conducted by researchers at Appalachian State University). For more information visit: http://www.longevinex.com or call 1 866-405-4000.

(1) Reference/ Resveratrol is not stable at room temperature without

protection from light. Research center: Department of Medicinal

Chemistry and Pharmacognosy, College of Pharmacy, University of

Illinois at Chicago, Chicago, Illinois. Title: An LC-MS method for

analyzing total resveratrol in grape juice, cranberry juice, and in

wine. Journal: Journal Agriculture Food Chemistry Volume 50, Number

3, pages 431-35, January 2002.

(2) Resveratrol is unstable against light, heat, wet-heating and oxygen.

Research center: College of Life Sciences and Engineering, Shaanxi

University of Science & Technology, Xianyang China. Title: Study on

the stability of resveratrol in rhizoma polygoni cuspidate. Journal:

Zhong Yao Cai. Volume 30, Number 7, pages 805-07, 2007.


'/>"/>
SOURCE Longevinex
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lincare Holdings Inc. Announces First Quarter 2008 Financial Results
2. Darwin to Announce First Quarter 2008 Financial Results
3. Omnicell Announces First Quarter 2008 Results
4. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2008 Financial Results
5. Old Orchard Introduces First Multi-Serve Vitamin Water, Sweetened with Agave Nectar and Real Fruit Juice
6. Survey offers first-ever look at treatment practices for nonepileptic seizures
7. HMS Holdings Corp. Hosts First Quarter 2008 Financial Teleconference and Presentation
8. Sorrento(R) Cheese Launches First Omega-3 Cheese on the Market
9. Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008
10. QLT announces first quarter 2008 Visudyne(R) sales
11. Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ... Angeles based healthcare technology company California Healthcom Group (CHG). , The HUG ... healthcare arena. With headquarters in California, CHG is a growing, internationally recognized healthcare ...
(Date:3/23/2017)... ... March 23, 2017 , ... Michael Lanteri Agency, an insurance ... Collins area, has unveiled a collaboration with nonprofit Big Bones Canine Rescue as ... worthy cause may now be made at http://bigbonescaninerescue.com/ . , Big Bones ...
(Date:3/23/2017)... Laguna Hills, CA (PRWEB) , ... March 23, ... ... in document management and workflow solutions, today named The Resource Group as their ... annual customer and partner conference in Newport Beach, CA. The award recognizes ...
(Date:3/23/2017)... ... , ... Sharon Kleyne, host of the nationally syndicated radio program, The Sharon ... talked on her program about how she is looking forward to World Water Day ... important distinction. World Water Day, Kleyne pointed out, is an occasion for looking ahead ...
(Date:3/23/2017)... , ... March 23, 2017 , ... It’s that time ... many students are thinking about summer internships , which can be frustrating when ... The pros at Garden Media Group, a boutique public relations firm outside of Philadelphia, ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology: